GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Fresenius SE & Co KGaA (XTER:FRE) » Definitions » EV-to-EBITDA

Fresenius SE KGaA (XTER:FRE) EV-to-EBITDA : 7.53 (As of May. 01, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Fresenius SE KGaA EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Fresenius SE KGaA's enterprise value is €29,295 Mil. Fresenius SE KGaA's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €3,888 Mil. Therefore, Fresenius SE KGaA's EV-to-EBITDA for today is 7.53.

The historical rank and industry rank for Fresenius SE KGaA's EV-to-EBITDA or its related term are showing as below:

XTER:FRE' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.98   Med: 9.64   Max: 13.5
Current: 7.53

During the past 13 years, the highest EV-to-EBITDA of Fresenius SE KGaA was 13.50. The lowest was 6.98. And the median was 9.64.

XTER:FRE's EV-to-EBITDA is ranked better than
76.52% of 460 companies
in the Healthcare Providers & Services industry
Industry Median: 13.09 vs XTER:FRE: 7.53

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-01), Fresenius SE KGaA's stock price is €27.97. Fresenius SE KGaA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.050. Therefore, Fresenius SE KGaA's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Fresenius SE KGaA EV-to-EBITDA Historical Data

The historical data trend for Fresenius SE KGaA's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fresenius SE KGaA EV-to-EBITDA Chart

Fresenius SE KGaA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.73 7.51 7.84 16.71 11.00

Fresenius SE KGaA Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.71 12.05 12.98 10.51 11.00

Competitive Comparison of Fresenius SE KGaA's EV-to-EBITDA

For the Medical Care Facilities subindustry, Fresenius SE KGaA's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fresenius SE KGaA's EV-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Fresenius SE KGaA's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Fresenius SE KGaA's EV-to-EBITDA falls into.



Fresenius SE KGaA EV-to-EBITDA Calculation

Fresenius SE KGaA's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=29294.747/3888
=7.53

Fresenius SE KGaA's current Enterprise Value is €29,295 Mil.
Fresenius SE KGaA's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €3,888 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fresenius SE KGaA  (XTER:FRE) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Fresenius SE KGaA's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=27.97/-1.050
=At Loss

Fresenius SE KGaA's share price for today is €27.97.
Fresenius SE KGaA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.050.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Fresenius SE KGaA EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Fresenius SE KGaA's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Fresenius SE KGaA (XTER:FRE) Business Description

Address
Else-Kroener-Strasse 1, Bad Homburg, HE, DEU, 61352
Fresenius SE is a healthcare holding company based in Germany with four segments. The company owns a large stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals and fertility clinics in Germany, Spain, and Latin America. Vamed provides a variety of services such as healthcare facility construction and operation management, including post-acute care rehabilitation.
Executives
Dr. Michael Moser Board of Directors
Sara Hennicken Board of Directors
Michael Sen Board of Directors
Dr. Francesco De Meo Board of Directors
Stephan Sturm Board of Directors
Wolfgang Kirsch Supervisory Board
Mats Henriksson Board of Directors
Dr. Gerd Krick Supervisory Board

Fresenius SE KGaA (XTER:FRE) Headlines

No Headlines